Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 13Completed 5Active not recruiting 5Unknown 4Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Small Cell Lung Carcinoma 3Cholangiocarcinoma 3Lung Neoplasms 2Liver Neoplasms 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Respiratory Tract Neoplasms 1Rare Tumour 1Pancreatic Neoplasms 1Pancoast Syndrome 1Ovarian Neoplasms 1Gallbladder Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 7Cisplatin 6Oxaliplatin 5Fluorouracil 4lenvatinib 3envafolimab 3S 1 (combination) 3Capecitabine 3toripalimab 2pembrolizumab 2Leucovorin 2Irinotecan 2Folfox protocol 2tislelizumab 1tegafur-gimeracil-oteracil 1surufatinib 1pertuzumab 1mitazalimab 1durvalumab 1disitamab vedotin 1camrelizumab 1anlotinib 1Simvastatin 1Self Expandable Metallic Stents 1Bevacizumab 1Albumin-Bound Paclitaxel 1Actigraphy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Biliary Tract Neoplasms × durvalumab × Clear all
NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Yonsei University

Phase 1/2 Not yet recruiting
160 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡